Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | rHSC-DIPGVax |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
rHSC-DIPGVax is a peptide vaccine comprising 16 heat shock protein (HSP) neoepitopes associated with diffuse intrinsic pontine glioma and diffuse midline glioma, which potentially enhances cytotoxic T-lymphocyte (CTL) response against HSP neoepitope-expressing tumor cells (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C192844 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Balstilimab + rHSC-DIPGVax | Balstilimab rHSC-DIPGVax | 0 | 1 |
| Balstilimab + rHSC-DIPGVax + Zalifrelimab | Balstilimab Zalifrelimab rHSC-DIPGVax | 0 | 1 |
| rHSC-DIPGVax | rHSC-DIPGVax | 0 | 1 |